Centre Hospitalier Intercommunal de Créteil

The Centre Hospitalier Intercommunal de Créteil is advancing treatment for non‑small cell lung cancer by evaluating novel immunotherapy combinations in patients with unresectable or metastatic disease.

• Evaluation of durvalumab combined with oleclumab after chemoradiation
• Evaluation of durvalumab combined with monalizumab after chemoradiation
• Progression‑free survival assessment using blinded independent central review

The goal of these studies is to extend survival and improve quality of life for individuals with Stage III or advanced NSCLC by testing more effective immune‑based regimens.

Researchers in the pneumology department are also exploring a TROP‑2‑directed antibody‑drug conjugate for patients with advanced or unresectable NSCLC.

• Assessment of anti‑TROP‑2 ADC efficacy in heavily pre‑treated patients
• Comprehensive biomarker analysis to identify responders
• Safety monitoring and quality‑of‑life evaluation

This work seeks to introduce a precision‑medicine option that targets tumor‑specific antigens, offering a potential new line of therapy for those with limited treatment choices.